Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

ARCT 11.14.2024

Full Press ReleaseSEC FilingsOur ARCT Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference | Presentation
  • 01.10.2025 - Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
  • 01.06.2025 - Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Recent Filings

  • 12.18.2024 - 4 Statement of changes in beneficial ownership of securities
  • 11.08.2024 - SC 13G Statement of Beneficial Ownership by Certain Investors
PDF Version

TOKYO--(BUSINESS WIRE)--Nov. 14, 2024--Meiji Seika Pharma Co., Ltd.(Headquarters:Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as "Meiji Seika Pharma") today announced its investment inARCALIS, Inc.(Headquarters: Minami-soma City, Fukushima Prefecture; President:Satoshi Takamatsu; hereinafter referred to as "ARCALIS").

ARCALISis a joint venture betweenAxcelead, Inc., which manages a group of world-class pharmaceutical and healthcare platform companies, andArcturus Therapeutics, Inc.a commercial mRNA medicines and vaccines company.ARCALISis engaged in the development of mRNA pharmaceuticals and vaccines, as well as contract development and manufacturing organization (CDMO) services. The company plans to establish a comprehensive system for the domestic production of mRNA vaccines, ranging from the development of manufacturing technologies to the production of both active pharmaceutical ingredients and formulations.

In response to the lessons learned from the delays experienced in the development of COVID-19 vaccines during the pandemic,ARCALISandMeiji Seika Pharmaare committed to advancing the development, production, and supply of mRNA vaccines in line with the "Strategy forStrengthening Vaccine Developmentand Production Systems" adopted by the Japanese government. This strategy is designed to ensure that the necessary quantities of vaccines are delivered to the population in a timely manner when they are needed.

This investment will further strengthen the collaborative relationship between the two companies. The combination ofARCALIS'advanced technology and operations in mRNA pharmaceuticals and vaccines withMeiji Seika Pharma'sexpertise in manufacturing, post-marketing safety management and stable product supply is expected to significantly improve the supply of mRNA vaccines inJapan.

Meiji Seika Pharmaplans to supply the domestically produced next-generation sa-mRNA vaccine (replicon) ‘KOSTAIVE® for Intramuscular Injection’ inDecember 2024. This vaccine will be formulated by aMeiji Seika Pharma Groupcompany using the active pharmaceutical ingredient produced byARCALIS. Supply will commence upon approval of the partial change in manufacturing and marketing authorization for the additional domestic manufacturing sites currently under application.

Meiji Seika Pharmais committed to the timely and reliable production and supply of essential vaccines to the public in response to potential future infectious diseases.

AboutMeiji Seika Pharma

Meiji Seika Pharma, since it launched penicillin in 1946, has been providing efficacious and high-quality pharmaceutical products including therapeutics and vaccines for infectious diseases, therapeutics for central nervous system diseases and generic drugs, to meet various medical needs.(https://www.meiji.com/global/pharmaceuticals/)

AboutARCALIS

ARCALISis an mRNA vaccines and therapeutics contract development and manufacturing organization (“CDMO”), jointly established byAxcelead, Inc.andArcturus Therapeutics, Inc..ARCALISaims to develop the world’s first mRNA vaccines and therapeutics CDMO business that promises a stable supply of high-quality mRNA medicines to all customers, including Arcturus, other pharmaceutical companies, biotech companies, and academic institutes worldwide. (https://corp.arcalis.co.jp/en/)

About Axcelead

Axcelead is a healthcare platform company that ownsAxcelead Drug Discovery Partners, Inc., Japan’s first drug discovery solution provider, andARCALIS Inc., a CDMO company capable of integrated manufacturing of mRNA pharmaceuticals. (https://www.axcelead-hd.com/en-home/)

AboutArcturus Therapeutics

Arcturus Therapeutics Holdings Inc.founded in 2013, is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. (https://arcturusrx.com/)

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241113734839/en/

Meiji Seika PharmaPublic RelationsSayoko Tagapr-pharma@meiji.com

Axcelead, Inc.&ARCALIS, Inc.Public Relations & Investor RelationsMitsuo Ogurimitsuo.oguri@axcelead.com

Arcturus TherapeuticsPublic Relations & Investor RelationsNeda SafarzadehVP, Head of IR/PR/Marketing(858) 900-2682IR@ArcturusRx.com

Source:Meiji Seika Pharma Co., Ltd.andARCALIS, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com